Leading brain-computer interface (BCI) company Strong Brain Tech has recently completed a funding round of approximately 20 billion yuan, not only setting a record for the second-largest financing in the global BCI field after Neuralink but also signaling a powerful endorsement from top-tier capital for the commercialization of this cutting-edge technology.
According to a January 6th report, this funding round featured an impressive lineup of investors, led by prominent institutions IDG and Walden International, and also included strategic industrial investors such as Lens Technology and Will Semiconductor. This massive capital injection comes at a time of growing global interest in the BCI sector, demonstrating a sharp increase in market confidence in the technology's transition from laboratory research to large-scale application.
Spurred by this news and Elon Musk's announcement that Neuralink will commence mass production in 2026, capital markets have reacted strongly. Since the start of trading in 2026, BCI concept stocks have performed robustly, with multiple stocks like Beiyikang and Sanbo Brain Science hitting consecutive daily limit-ups, while others such as Sinomed, Guanhao Biotech, Aipeng Medical, Meihao Medical, Xiangyu Medical, and Lepu Medical surged by the 20% daily limit. Investors are actively reassessing the commercial prospects and valuation potential of this critical technology field.
The deep involvement of supply chain giants like Lens Technology further validates the industry's trend of crossing over from R&D to mass production. As the exclusive supplier for Strong Brain Tech's core hardware modules, Lens Technology stated it is leveraging its precision manufacturing capabilities to actively pursue more collaborations, indicating an accelerated integration of the upstream and downstream industrial chain.
This funding round combined support from both financial investors and industrial capital. Investors included IDG Capital and Walden International, founded by Intel CEO Lip-Bu Tan. Furthermore, strategic investors such as "Apple supply chain" giant Lens Technology, Lingyi iTech, along with Will Semiconductor, Runze Technology, Huazhu Group, and TAL Education Group were all present. The list also featured top-tier family offices from Hong Kong, China, and the United States.
A significant highlight of this funding is the deep integration with the industrial chain. Lens Technology confirmed in a January 6th response to investor inquiries that it is a strategic investor in Strong Brain Tech and holds the exclusive contract for mass-producing its core hardware modules. In November 2025, Lens Technology and Strong Brain Tech jointly donated a large batch of intelligent bionic limbs to the Hunan Provincial Disabled Persons' Federation, the core modules of which originated from Lens Technology's production lines. This "capital + manufacturing" cooperation model provides a supply chain guarantee for the large-scale deployment of BCI products.
As a "unicorn" in the BCI field, Strong Brain Tech is grouped with companies like DeepSeek and Yushu Technology as part of the "Hangzhou Six Little Dragons." The company focuses on BCI product development and is one of the very few global enterprises to have achieved scaled mass production of products. It has already obtained U.S. FDA certification and European CE marking, with its R&D investment ranking among the highest in the industry.
The catalyst igniting the recent market rally stemmed from updates from its main competitor, Neuralink. Musk announced on January 1st that Neuralink would begin mass production of devices in 2026 and advance fully automated surgical solutions; he subsequently stated on January 3rd that he was confident in helping paralyzed individuals regain full-body function. These two significant pieces of news validated the technical feasibility and directly contributed to consecutive daily limit-ups for concept stocks like Beiyikang, Xiangyu Medical, and Meihao Medical following the market opening in 2026.
Strong Brain Tech was founded in 2015 by Harvard alumnus Han Bicheng. Its technological approach emphasizes non-invasive brain-computer interfaces, establishing signal pathways between the brain and external devices to provide solutions for rehabilitation of disabled individuals and treatment of brain diseases. Han previously stated that BCI is transforming from laboratory research into a key technology impacting daily life, with the future potential to make the human brain "transparent."
Regarding commercial application, Strong Brain Tech's core product, the "Super Sensor," can detect faint brainwave information without craniotomy, converting it into neural signals to control external devices. Currently, its products can assist individuals with physical disabilities in performing activities like running and complex sports. Han Bicheng has proposed a plan to help 1 million physically disabled individuals regain freedom of movement and assist 10 million patients with Alzheimer's disease, autism, and insomnia in rehabilitation within the next 5 to 10 years.
Regarding the next steps in capital markets, Bloomberg previously reported that Strong Brain Tech might pursue an initial public offering (IPO) in Hong Kong or mainland China. Individuals familiar with the matter disclosed to media that the company has begun preparing listing documents, but the specific location and details have not been finalized, with related discussions still subject to change.
With China increasing its investment in brain science and the BCI field—the so-called "Brain Project" initiative—and with leading companies like Strong Brain Tech securing funding, the sector is accelerating into a new phase of technological realization and commercial breakthrough.
Comments